- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02660151
Study of Using the Hyper-CL™ Lens (Hyper Osmotic Contact Lens) in Subjects Suffering From Corneal Edema
Prospective, Randomized Crossover Study of Using the Hyper-CL™ Lens (Hyper Osmotic Contact Lens) in Subjects Suffering From Corneal Edema
The Hyper-CL™ lenses are indicated for therapeutic use as a bandage to protect the corneal surface and to relieve corneal pain in the treatment of acute or chronic ocular pathologies, such as bullous keratopathy, corneal erosions, entropion, corneal edema, and corneal dystrophies as well as post-surgical conditions resulting from cataract extraction and corneal surgery. The lenses may be prescribed for daily wear with removal for cleaning and disinfection (chemical, not heat) prior to reinsertion, as recommended by the eye care professional.
In addition Hyper-CL™ contact lenses can also provide optical correction during healing if required.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is a prospective, randomized crossover study. The primary aim of this study is to assess the safety and effectiveness of using the Hyper-CL™ lens +salt solution (5% NaCl) as compared with using regular contact lens + salt solution (5% NaCl) in subjects suffering from corneal edema. Safety will be assessed by evaluating the rate of adverse events and adverse device effects occurred throughout the study period. Effectiveness will be assessed by measuring changes in corneal thickness and visual acuity.
Subjects with corneal edema will be the study population. Only subjects who have signed the informed consent form and meet all the eligibility criteria listed below will be qualified for enrollment. The study will encompass a total of up to 80 subjects who will complete the Protocol follow-up schedule.
Each subject will be treated with:
Treatment A: Hyper-CL™ lens + salt solution + antibiotics drops (7 days) Treatment B: Regular soft contact lens +salt solution+ antibiotics drops (7 days) One week (7 days) of washout without any treatment will be between treatments. Subject will be equally allocated to one of the following 2 crossover regimen based on a randomization scheme with blocks stratified by center: A-B; B-A
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject is over 18 years old
- Subject with corneal edema in the visual access
- Subject with visual acuity of 6/20 or worse (equivalent ETDRS) clinically explained by corneal edema
- Subject understands the study requirements and the treatment procedures and provides written Informed Consent before any study-specific tests or procedures are performed.
Exclusion Criteria:
- Subject with active Herpes keratitis
- Subject with scarred cornea
- Subject who is suffering from erosions and/or infections of the cornea (red eye)
- Subject with glaucoma shunts (e.g. Ahmed valve) and or bleb
- Subject who require chronic administration of any topical ophthalmic beside lubrication eye drops and steroids or anti glaucoma drags
- Subject who is currently participating or have participated in an investigational study, other than this study, within the past 60 days
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment A-B
Treatment A: Hyper-CL™ lens + salt solution + antibiotics drops (7 days) Treatment B: Regular soft contact lens +salt solution+ antibiotics drops (7 days) One week (7 days) of washout without any treatment will be between treatments.
|
|
Experimental: Treatment B-A
Treatment A: Hyper-CL™ lens + salt solution + antibiotics drops (7 days) Treatment B: Regular soft contact lens +salt solution+ antibiotics drops (7 days) One week (7 days) of washout without any treatment will be between treatments.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
frequency and severity of all treatment-related adverse events
Time Frame: Up to 28 days (or 21 days if wash out is not needed).
|
Up to 28 days (or 21 days if wash out is not needed).
|
|
Percent of subjects with corneal thickness decrease of at least 8% and or visual acuity improvement of at least 1 line following treatment with the Hyper-CL™ lens + salt solution
Time Frame: Up to 28 days (or 21 days if wash out is not needed).
|
assess by physiological parameter
|
Up to 28 days (or 21 days if wash out is not needed).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent of subjects with corneal thickness decrease of at least 8%.
Time Frame: Up to 28 days (or 21 days if wash out is not needed).
|
assess by physiological parameter
|
Up to 28 days (or 21 days if wash out is not needed).
|
Percent of subjects with visual acuity improvement of at least 1 line
Time Frame: Up to 28 days (or 21 days if wash out is not needed).
|
assess by physiological parameter
|
Up to 28 days (or 21 days if wash out is not needed).
|
Corneal thickness decrease
Time Frame: Up to 28 days (or 21 days if wash out is not needed).
|
assess by physiological parameter
|
Up to 28 days (or 21 days if wash out is not needed).
|
change in Measurement Best Corrected Distance Visual Acuity (BCDVA)
Time Frame: Up to 28 days (or 21 days if wash out is not needed).
|
Up to 28 days (or 21 days if wash out is not needed).
|
|
change in Subject comfort questionnaire
Time Frame: Up to 28 days (or 21 days if wash out is not needed).
|
Up to 28 days (or 21 days if wash out is not needed).
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ECL00030
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on CORNEAL EDEMA
-
Aurion BiotechRecruitingCorneal Edema | Corneal Endothelial DysfunctionUnited States, Canada
-
Eye-yon MedicalCompletedCorneal EdemaIsrael
-
Tiedra Farmacéutica SLHospital Universitario Principe de AsturiasUnknown
-
Eye-yon MedicalCompletedChronic Cornel EdemaNetherlands, Israel, Germany, Spain
-
Aurion BiotechCompleted
-
Nicole Fram M.D.RecruitingAnterior Chamber Inflammation | Ocular Pain | Corneal Edema | Corneal Defect | Corneal Staining | Visual Outcome | CME - Cystoid Macular EdemaUnited States
-
Eye-yon MedicalActive, not recruitingCorneal EdemaIsrael, Georgia, Germany, India, France, Netherlands
-
Prince of Songkla UniversityCompletedIntraocular Pressure | Corneal EdemaThailand
-
Kowa Research Institute, Inc.CompletedA Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Cataract SurgeryCorneal Edema After Cataract SurgeryUnited States, Puerto Rico
-
Rabin Medical CenterUnknownCorneal Edema | Visual AcuityIsrael
Clinical Trials on Hyper-CL™ lens
-
Eye-yon MedicalCompleted
-
Eye-yon MedicalCompletedCorneal EdemaIsrael
-
Naval Medical Research CenterUnknownLeishmaniasis, CutaneousPeru
-
LEC Eye CentreAlcon ResearchCompletedCataract Senile | Intraocular Lens ComplicationMalaysia
-
Alcon ResearchAston UniversityCompleted
-
Johnson & Johnson Vision Care, Inc.CompletedVision Satisfaction in Bright LightSpain, United Kingdom
-
Alcon ResearchCompletedRefractive Error | MyopiaUnited Kingdom
-
University of Washington, the Collaborative Health...Cystic Fibrosis FoundationCompleted
-
CF Therapeutics Development Network Coordinating...National Heart, Lung, and Blood Institute (NHLBI); Cystic Fibrosis FoundationCompleted
-
Coopervision, Inc.Completed